产地国家:美国处方药:是所属类别: 300毫克/0.5升/注射器 1注射器/盒包装规格: 300毫克/0.5升/注射器 1注射器/盒计价单位:盒生产厂家英文名:Sandoz原产地英文商品名:ZARXI 300mcg/0.5 mL/SYRINGE 1SYRINGE/box原产地英文药品名:filgrastim-sndz中文参考商品译名:Neulasta 300毫克/0.5升/注射器 1注射器/盒中文...
Biosimilar Uptake in Medicare Part B Varied Across Hospital Outpatient Departments and Physician Practices: The Case of Filgrastim Objectives To examine the uptake of filgrastim-sndz (Zarxio), the first biosimilar to launch in the United States, in the Medicare Part B fee-for-service p... MP So...
Raedler LA, Zarxio RLA. Zarxio (Filgrastim-sndz): First Biosimilar Approved in the United States. Am Health Drug Benefits 2016;9:150-4.Raedler LA. Zarxio (filgrastim-sndz): first biosimilar approved in the United States. Am Health Drug Benefits. 2016;9(Spec Feature): 150-154....
Zarxio (filgrastim-sndz) Febrile Neutropenia Prophylaxis Myelosuppressive chemotherapy Nonmyeloid malignancy Indicated to decrease incidence of infection (ie, febrile neutropenia) in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a significant incidence of severe ...
Sandoz, a Novartis company, announced today that the US Food and Drug Administration (FDA) approved Zarxio(TM) (filgrastim-sndz) for all indications included in the reference product's label. Sandoz is the first company to receive approval of a biosimilar in the US through the new F...
The U.S. Food and Drug Administration today approved Zarxio (filgrastim-sndz), the first biosimilar product approved in the U.S. US Food,D Administration - Office of the Commissioner 被引量: 93发表: 2015年 Zarxio (Filgrastim-sndz): First Biosimilar Approved in the United States Zarxio (filgr...
回答:匿名Sandoz得到了对filgrastim-sndz Zarxio (,) Amgen的filgrastim Neupogen的一个biosimilar版本的许可 ()。 2013-05-23 12:24:58 回答:匿名山德士获得非-sndz (Zarxio),安进的非 (药水) 仿制版本的审批。 2013-05-23 12:26:38 回答:匿名正在翻译,请等待... 2013-05-23 12:28:18 回答:匿名...
The Food and Drug Administration has approved Zarxio (filgrastim-sndz), a biosimilar to filgrastim (Neupogen, marketed by Amgen Inc.). The drug binds to the granulocyte colony-stimulating factor (G-CSF) receptor, and is widely prescribed to treat neutropenia. The approval of Zarxio is...
FDA Approves First Biosimilar for U.S.—Zarxio (Filgrastim-sndz)An abstract is unavailable.DiGiulioSarah
Cost savings of filgrastim-sndz using WAC + CPT were even greater under all scenarios.Prophylaxis with filgrastim-sndz, a biosimilar filgrastim, was associated consistently with significant cost-savings over prophylaxis with reference filgrastim, pegfilgrastim, and pegfilgrastim-injector, and this ...